Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults

ClinicalTrials.gov ID: NCT05703607

Public ClinicalTrials.gov record NCT05703607. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A PHASE 1/2 RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this clinical study is to learn about the safety, extent of the side effects (reaction to vaccine), and immune response (your immune system's reaction) of the study vaccine called Varicella Zoster Virus modRNA (VZV modRNA). We are seeking for healthy participants 50 through 85 years of age. This study will be conducted in 2 substudies: Substudy A (Phase 1) and Substudy B (Phase 2). Substudy A: This substudy is the Phase 1 portion of the study. In this substudy, participants will receive 1 of 3 VZV modRNA vaccine candidates (different construct, different dose levels and different formulation \[frozen or freeze dry powder\]) or the approved shingles vaccine intramuscularly. Participants will be assigned in 1 of 10 groups in the study. Vaccination will be given either as a 2-dose series using one of two dosing schedules (either 2-months apart or 6-months apart), or (in one of the groups), as a single VZV modRNA vaccine at the first vaccination visit and saline at the second vaccination visit. Participants will take part in this study for 8 to 12 months depending on the group they are assigned to. Some group(s) will continue into persistence-of-immunity (overtime assessment of effect of vaccine) portion of the study. Those participants assigned to these selected groups will be involved in the study for up to 5 years. Substudy B: This substudy is the Phase 2 portion of the study. In this part of the study, participants will receive either VZV modRNA vaccine at selected dose level/schedule/formulation or approved shingles vaccine. This selection was determined from data collected in Substudy A. Participants will be involved in this study for up to 5 years.

Study identification

NCT ID
NCT05703607
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Pfizer
Industry
Enrollment
484 participants

Conditions and interventions

Eligibility (public fields only)

Age range
50 Years to 85 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 25, 2023 (Actual)
Primary completion
Sep 23, 2025 (Actual)
Completion
Sep 23, 2025 (Actual)
Last update posted
May 4, 2026

2023 – 2025

United States locations

U.S. sites
35
U.S. states
18
U.S. cities
27
Facility City State ZIP Site status
Tri-City Cardiology Gilbert Arizona 85233 —
Aventiv Research Inc. Mesa Arizona 85206 —
Stanford University Medical Center Palo Alto California 94304 —
Diablo Clinical Research, Inc. Walnut Creek California 94598 —
GW Medical Faculty Associates Washington D.C. District of Columbia 20037 —
GW Vaccine Research Unit Washington D.C. District of Columbia 20037 —
Proactive Clinical Research,LLC Fort Lauderdale Florida 33308 —
Acevedo Clinical Research Associates Miami Florida 33142 —
East-West Medical Research Institute Honolulu Hawaii 96814 —
West Valley Cardiology Services Meridian Idaho 83642 —
Solaris Clinical Research Meridian Idaho 83646 —
University of Iowa Iowa City Iowa 52242 —
Johnson County Clinical Trials Lenexa Kansas 66219 —
Centennial Medical Group Columbia Maryland 21045 —
Associates in Cardiology, PA Silver Spring Maryland 20910 —
C.S. Mott Clinical Research Center (CRC) Detroit Michigan 48201 —
Henry Ford St. John Hospital Grosse Pointe Woods Michigan 48236 —
Velocity Clinical Research, Norfolk Norfolk Nebraska 68701 —
Quality Clinical Research Omaha Nebraska 68114 —
University of Nevada School of Medicine - Reno Reno Nevada 89557 —
South Jersey Infectious Disease Somers Point New Jersey 08244 —
IMA Clinical Research Albuquerque New Mexico 87109 —
NYU Langone Health New York New York 10016 —
Tisch Hospital New York New York 10016 —
Icahn School of Medicine at Mount Sinai New York New York 10029 —
Rochester Clinical Research, LLC Rochester New York 14609 —
Accellacare - Wilmington Wilmington North Carolina 28401 —
Wilmington Health, PLLC (Cardiologist) Wilmington North Carolina 28401 —
CTI Clinical Research Center Cincinnati Ohio 45212 —
Centricity Research Columbus Ohio Multispecialty Columbus Ohio 43213 —
Columbus Cardiovascular Associates, Inc. Columbus Ohio 43213 —
Clinical Trials of Texas, LLC dba Flourish Research San Antonio Texas 78229 —
Clinical Trials of Texas, LLC San Antonio Texas 78229 —
IMA Clinical Research San Antonio San Antonio Texas 78229 —
Dynamed Clinical Research, LP d/b/a DM Clinical Research Tomball Texas 77375 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05703607, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 4, 2026 · Synced Oct 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT05703607 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →